CTMX vs. SKYE, CRVO, IMAB, RENB, INCR, RPTX, SYRS, PRQR, SCPH, and PRLD
Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Skye Bioscience (SKYE), CervoMed (CRVO), I-Mab (IMAB), Renovaro (RENB), InterCure (INCR), Repare Therapeutics (RPTX), Syros Pharmaceuticals (SYRS), ProQR Therapeutics (PRQR), scPharmaceuticals (SCPH), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
Skye Bioscience presently has a consensus price target of $22.50, suggesting a potential upside of 86.72%. CytomX Therapeutics has a consensus price target of $6.53, suggesting a potential upside of 245.50%. Given Skye Bioscience's higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Skye Bioscience.
CytomX Therapeutics received 370 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 66.01% of users gave CytomX Therapeutics an outperform vote.
In the previous week, CytomX Therapeutics had 6 more articles in the media than Skye Bioscience. MarketBeat recorded 8 mentions for CytomX Therapeutics and 2 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.61 beat CytomX Therapeutics' score of -0.58 indicating that CytomX Therapeutics is being referred to more favorably in the news media.
Skye Bioscience has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
CytomX Therapeutics has a net margin of 13.87% compared to CytomX Therapeutics' net margin of 0.00%. Skye Bioscience's return on equity of -30.70% beat CytomX Therapeutics' return on equity.
CytomX Therapeutics has higher revenue and earnings than Skye Bioscience.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
CytomX Therapeutics beats Skye Bioscience on 11 of the 14 factors compared between the two stocks.
Get CytomX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytomX Therapeutics Competitors List
Related Companies and Tools
